SCHEMBL20111247

SCHEMBL20111247

CCCCOc1cc2c(c(F)c1F)-c1c-2ccc(CCc2ccc(OCC)c(F)c2F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.35
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
TDP1 Q9NUW8 3/20 0.34
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 3/20 0.34
CYP2D6 P10635 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
GLA P06280 1/20 0.33
CNR2 P34972 1/20 0.32
MAPT P10636 3/20 0.31
ATM Q13315 2/20 0.31
RAB9A P51151 1/20 0.31
HPGD P15428 1/20 0.31
CDC25A P30304 1/20 0.31
CDC25B P30305 1/20 0.31
CDC25C P30307 1/20 0.31
CYP2C9 P11712 2/20 0.31
THRA P10827 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20102390 0.85 L3MBTL1 (0.42) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6
SCHEMBL20102530 0.83 CTSL (0.34) CTSLCTSSCTSKMAPTFGFR2
SCHEMBL20102405 0.81 FGFR2 (0.34) L3MBTL1CTSLCTSSCTSKTDP1
SCHEMBL20102404 0.79 CTSL (0.39) L3MBTL1CTSLCTSSCTSKSMN1; SMN2
SCHEMBL20102470 0.79 FGFR2 (0.33) CTSLCTSSCTSKFGFR2
SCHEMBL20102406 0.78 THRB (0.37) L3MBTL1CTSLCTSSCTSKSMN1; SMN2
SCHEMBL20111337 0.78 GABRA1 (0.33) CTSLCTSSCTSKFGFR2ALDH1A1
SCHEMBL21869910 0.78 CNR2 (0.39) L3MBTL1CTSLCTSSCTSKTDP1
SCHEMBL14356142 0.77 CTSS (0.47) L3MBTL1CTSLCTSSCTSKTDP1
SCHEMBL29444864 0.76 L3MBTL1 (0.47) L3MBTL1TDP1CYP1A2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed
EP-3315583-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC Corporation (JP) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S L3MBTL1 177/4885CTSL 2729/4885CTSS 2436/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S L3MBTL1 177/4885CTSL 2729/4885CTSS 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.